Report of Foreign Issuer (6-k)
February 28 2017 - 4:01PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM
6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF
1934
For the month of February
2017.
Commission File
Number:
000-53805
Intellipharmaceutics International
Inc.
(Translation of
registrant's name into English)
30 WORCESTER ROAD TORONTO, ONTARIO M9W
5X2
(Address of principal
executive office)
Indicate by check
mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F. Form 20-F [ x ] Form
40-F [ ]
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Note:
Regulation S-T Rule 101(b)(1) only
permits the submission in paper of a Form 6-K if submitted solely
to provide an attached annual report to security
holders.
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):
Note: Regulation S-T
Rule 101(b)(7) only permits the submission in paper of a Form 6-K
if submitted to furnish a report or other document that the
registrant foreign private issuer must furnish and make public
under the laws of the jurisdiction in which the registrant is
incorporated, domiciled or legally organized (the
registrant’s “home country”), or under the rules
of the home country exchange on which the registrant’s
securities are traded, as long as the report or other document is
not a press release, is not required to be and has not been
distributed to the registrant’s security holders, and, if
discussing a material event, has already been the subject of a Form
6-K submission or other Commission filing on EDGAR.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
|
Intellipharmaceutics International
Inc.
(Registrant)
|
Date: February 27,
201
|
|
/s/
Domenic Della Penna
Domenic Della
Penna
Chief Financial Officer
|
EXHIBIT LIST
Exhibit
|
Description
|
99.1
|
Annual Information
Form
|
99.2
|
Form 52-109F1 - Chief
Executive Officer
|
99.3
|
Form 52-109F1 - Chief
Financial Officer
|
|
|
IntelliPharmaCeutics (QB) (USOTC:IPCIF)
Historical Stock Chart
From Apr 2024 to May 2024
IntelliPharmaCeutics (QB) (USOTC:IPCIF)
Historical Stock Chart
From May 2023 to May 2024